设为主页 | 联系我们 | 办公邮箱
logo logo文字
 
中心动态
您的位置:首页 - 新闻中心 - 美国默克公司研发高层访问中国牛津国际医学研究中心 - 正文

美国默克公司研发高层访问中国牛津国际医学研究中心美国默克公司研发高层访问中国牛津国际医学研究中心

2010/9/22 14:03:25



美国默克公司默克研究实验室高级副总裁Michael Mendelsohn一行访问中国牛津国际医学研究中心

      9月17日,美国默克公司默克研究实验室高级副总裁兼动脉粥样硬化及心血管疾病学负责人Michael Mendelsohn、副总裁Daniel Bloomfield、Francis Plat及默克新药技术产品合作引进(中国大陆香港台湾)总监Jennifer Hu访问中国牛津国际医学研究中心,与中国牛津国际医学研究中心主任蒋立新就双方在大规模临床试验的合作前景进行会谈。

 

 

中国牛津国际医学研究中心主任蒋立新介
绍中心大规模临床试验的有关情况 

默克研究实验室高级副总裁Michael Mendelsohn
认真听取蒋立新主人的介绍

      会谈中,蒋立新主任应高级副总裁Michael Mendelsohn一行的要求,首先介绍了基于20余年的实践经验,中国牛津国际医学研究中心如何开创性地建立了一整套确保国际、大规模、多中心临床试验在中国可靠的、高效实施的独特管理体系,并以多个不同类型的临床试验项目为例详细阐述了各自的组织实施模式和管理构架特点等。

 

 

 默克研究实验室高级副总裁Michael Mendelsohn、副总裁Daniel Bloomfield、Francis Plat及默克新药技术产品合作引进(中国大陆香港台湾)总监Jennifer Hu与中国牛津国际医学研究中心主任蒋立新认真交流

      Michael Mendelsohn副总裁在会谈中指出,目前国际越来越多的跨国制药公司把包括大规模、国际多中心临床试验在内的各类药物临床研究引入中国,中国正面临前所未有的大规模参与国际药物研究合作领域的良好机遇,但是在中国如何科学可靠地取得研究的最终成功同样也面临诸多困难和挑战。中国牛津国际医学研究中心根据中国实际情况,在实践中逐渐摸索和建立的一整套具有中国特色的组织运行大规模、多中心临床研究的管理体系,科学可靠地完成了一系列临床研究,产生了广泛的国际影响,成为这一领域的成功典范。正因为如此,美国默克公司不仅希望保持和巩固与阜外心血管病医院和中国牛津国际医学研究中心的原有合作基础,更希望进一步拓展和深化双方的合作领域。

      Michael副总裁还就默克公司与中国牛津国际医学研究中心近期在心血管领域准备开展的几个药物研究项目征询蒋立新主任等的意见,并表达希望建立双方联合研究中心的合作意向。蒋主任对Michael副总裁提出的新的合作项目兴趣浓厚,并对上访建立合作中心的意向表示赞同,希望接下来双方进行更有针对性的交流,争取尽早将各种合作意向变成现实。

      会谈结束时,蒋立新主任对美国默克公司为推动双方合作所做出的积极努力和显示的极大诚意表示感谢,认为能够与美国默克公司这样一个拥有世界一流的研发实力的公司合作也是促进中国牛津国际医学研究中心发展,不断提高中心科研水平的良好途径,相信双方的强强联合不仅互利共赢,更为重要的是可以共同推动中国心血管领域的整体研究水平的提高,研究成果不仅有利于中国人民,也为人类健康事业的发展做出了积极贡献。



附Micheal 的个人简介

MICHAEL MENDELSOHN, MD
Senior Vice President, Franchise Head, Cardiovascular
Merck Research Laboratories, Rahway, New Jersey, U.S.A.

 

Michael Mendelsohn is senior vice president and franchise head, cardiovascular, at Merck Research Laboratories (MRL). In this role, he has overall responsibility for scientific direction across drug discovery and development for cardiovascular research. He also works with the company's Global Human Health division to closely align Merck's research and marketing functions.

Prior to his time at Merck, Dr. Mendelsohn spent 17 years at Tufts Medical Center, where he served as the first-ever chief scientific officer and the executive director of the center's Molecular Cardiology Research Institute. He was also the first recipient of the Elisa Kent Mendelsohn Professorship of Molecular Cardiology and Medicine at Tufts University School of Medicine.

As a physician-scientist, Dr. Mendelsohn has focused on signal transduction pathways regulating vascular tone and function. His laboratory at Tufts contributed importantly to deciphering the mechanisms of action of endogenous vascular protective molecules, including receptors and pathways implicated in cardiovascular disease. Additionally, he has been the principal investigator on numerous National Institutes of Health awards, including a Specialized Center of Research (SCOR) in Ischemic Heart Disease and a Program Project Grant studying molecular mechanisms of vascular relaxation.

Dr. Mendelsohn serves on the editorial board of several publications and has published nearly 150 peer-reviewed articles on numerous cardiovascular disease-related topics. He was an invited speaker at the Nobel Symposium, "Estrogen and Women's Health" in Sweden in 1999 and for the 2008 Nobel Conference, "Recent Advances in Understanding Estrogen Signaling. " Dr. Mendelsohn received an undergraduate degree in chemistry and English from Amherst College and received his medical degree from Harvard Medical School. He completed his residency in internal medicine and fellowship in cardiovascular medicine at the Brigham and Womenís Hospital (BWH). Dr. Mendelsohn was a member of the faculty of the BWH Cardiology Division from 1988 to 1993 and an assistant professor of medicine at Harvard Medical School.

Abstract

Merck has a more than a fifty year history in cardiovascular disease (CVD) research and in bringing novel CVD therapies to physicians and patients, with a major impact on CVD morbidity and mortality. Amongst the many innovative therapies developed by Merck over this time are first-in-class diuretics, ACE inhibitors, angiotensin receptor blockers and statins. These medicines have contributed to a major reduction in the incidence of CVD. However, despite enormous benefits from existing therapies, CVD remains the leading cause of death worldwide, accounting for approximately 1/3 of all mortality. WHO data show that there is a global epidemic of CVD, with nearly 17M global CVD deaths annually at present. CVD is now estimated to be the leading cause of death in both established and developing countries worldwide and 25 million CVD deaths worldwide are expected by 2020, without obvious geographic, gender or socioeconomic boundaries. In China, aging and population growth are predicted to increase CVD by more than fifty percent over the coming 20 years, and projected unfavorable trends in other risk factors likely will accelerate this Chinese CVD epidemic.

Reduction in CVD morbidity and mortality requires improvements in risk factor and lifestyle management and better compliance with existing therapies, as well as finding new and better ways of targeting therapies to appropriate patients. Building on the deep heritage of scientific excellence in cardiovascular medicine, today's Merck has a major commitment to treating CVD now and for the future. A cornerstone of Merck's approach is a focus on developing new therapies for disease segments with substantial unmet medical need in which there are no existing drugs or current therapies are ineffective. The new disease areas of focus for CVD at Merck include new therapies for stroke, acute coronary syndrome and high risk CVD, particularly in patients with multiple metabolic risk factors associated with visceral adiposity and insulin resistance; resistant forms of hypertension; pulmonary arterial hypertension; and segments of the heart failure population. Merck has a robust pipeline of innovative therapies that offer promise to reduce CVD burden worldwide. These include: vorapaxar, a novel anti-platelet agent for the treatment of acute coronary syndrome and high risk CAD and the first Par-1 thrombin receptor antagonist; two novel lipid modifying therapies, anacetrapib, a CETP inhibitor, and Tredaptive, a novel niacin therapy, to treat patients with high risk CAD; and the Factor Xa inhibitor betrixaban, a new anti-thrombotic with reduced risk of bleeding designed for stroke prevention in atrial fibrillation patients and treatment of venous thrombotic disease. Merck also continues to invest in a major discovery organization that is extensively partnered with the global scientific community and dedicated to driving future innovation for CV disease.


文/肖巍  图/戴浩  审核/王舒娟
中国牛津国际医学研究中心

 
 

Copyright@ 2013-2018 中国医学科学院阜外医院 国家心血管疾病临床医学研究中心
通讯地址:北京市门头沟区石龙西路阜外医院西山园区C楼 邮政编码:102308
电子邮箱:ncrc@fuwaihospital.org